Movement Alert｜Akeso Inc Rises 4.8% in Regular Trading, Innovative Drug Payment Reform Catalyzes Biotech Sector Rally

Market Focus07-03

On July 3, Akeso Inc rose 4.8% in regular trading, trading at HKD 100.5/share, with turnover of HKD 224 million.

On the news front, China's National Healthcare Security Administration published the initial review results for the 2026 basic medical insurance directory and commercial insurance innovative drug directory, with 557 drugs passing the medical insurance directory review and 54 drugs passing the commercial insurance directory review. This marks the substantive advancement of the dual-directory negotiation mechanism combining public and commercial insurance. CITIC Construction Investment noted optimism for innovative drug enterprises' insurance access and incremental commercial insurance opportunities.

On the company level, all indications of Akeso's five self-developed drugs have been included in national medical insurance, while its new drug Qiyoukang has completed its first nationwide delivery, expected to accelerate market penetration. The broader biotech sector rallied in tandem, with 3SBio up 6.78%, Remegen up 6.87%, SKB Bio up 6.5%, and BeiGene up 4.81%, reflecting strong sector beta momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199758379?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199758379","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Inc Rises 4.8% in Regular Trading, Innovative Drug Payment Reform Catalyzes Biotech Sector Rally","media":"Market Focus","content":"<p><p>On July 3, Akeso Inc rose 4.8% in regular trading, trading at HKD 100.5/share, with turnover of HKD 224 million.</p><p>On the news front, China's National Healthcare Security Administration published the initial review results for the 2026 basic medical insurance directory and commercial insurance innovative drug directory, with 557 drugs passing the medical insurance directory review and 54 drugs passing the commercial insurance directory review. This marks the substantive advancement of the dual-directory negotiation mechanism combining public and commercial insurance. CITIC Construction Investment noted optimism for innovative drug enterprises' insurance access and incremental commercial insurance opportunities.</p><p>On the company level, all indications of Akeso's five self-developed drugs have been included in national medical insurance, while its new drug Qiyoukang has completed its first nationwide delivery, expected to accelerate market penetration. The broader biotech sector rallied in tandem, with 3SBio up 6.78%, Remegen up 6.87%, SKB Bio up 6.5%, and BeiGene up 4.81%, reflecting strong sector beta momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Inc Rises 4.8% in Regular Trading, Innovative Drug Payment Reform Catalyzes Biotech Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Inc Rises 4.8% in Regular Trading, Innovative Drug Payment Reform Catalyzes Biotech Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-03 09:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 3, Akeso Inc rose 4.8% in regular trading, trading at HKD 100.5/share, with turnover of HKD 224 million.</p><p>On the news front, China's National Healthcare Security Administration published the initial review results for the 2026 basic medical insurance directory and commercial insurance innovative drug directory, with 557 drugs passing the medical insurance directory review and 54 drugs passing the commercial insurance directory review. This marks the substantive advancement of the dual-directory negotiation mechanism combining public and commercial insurance. CITIC Construction Investment noted optimism for innovative drug enterprises' insurance access and incremental commercial insurance opportunities.</p><p>On the company level, all indications of Akeso's five self-developed drugs have been included in national medical insurance, while its new drug Qiyoukang has completed its first nationwide delivery, expected to accelerate market penetration. The broader biotech sector rallied in tandem, with 3SBio up 6.78%, Remegen up 6.87%, SKB Bio up 6.5%, and BeiGene up 4.81%, reflecting strong sector beta momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1199758379","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199758379","pubTimestamp":1783042551,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 3, Akeso Inc rose 4.8% in regular trading, trading at HKD 100.5/share, with turnover of HKD 224 million.On the news front, China's National Healthcare Security Administration published the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动向提示|康方生物常规交易涨4.8%创新药支付改革催化生物科技板块涨势","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On July 3, Akeso Inc rose 4.8% in regular trading, trading at HKD 100.5/share, with turnover of HKD 224 million.On the news front, China's National Healthcare Security Administration published the initial review results for the 2026 basic medical insurance directory and commercial insurance innovative drug directory, with 557 drugs passing the medical insurance directory review and 54 drugs passing the commercial insurance directory review. This marks the substantive advancement of the dual-directory negotiation mechanism combining public and commercial insurance. CITIC Construction Investment noted optimism for innovative drug enterprises' insurance access and incremental commercial insurance opportunities.On the company level, all indications of Akeso's five self-developed drugs have been included in national medical insurance, while its new drug Qiyoukang has completed its first nationwide delivery, expected to accelerate market penetration. The broader biotech sector rallied in tandem, with 3SBio up 6.78%, Remegen up 6.87%, SKB Bio up 6.5%, and BeiGene up 4.81%, reflecting strong sector beta momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199758379","isCrawlerRequest":true}